This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets,...

    $4,950.00
  2. 29 Sep 2015  |  Europe

    Analysis of the European Digital and Computed Radiography Markets

    Workflow Integration Provides Potential for Growth

    This research service presents an analysis of the digital and computed radiography markets in Europe. It also provides an in-depth analysis of the market and discusses market characteristics such as size, revenue forecasts, drivers, restraints, market penetration and market attractiveness for both the digital radiography (DR) and the computed rad...

    $4,950.00
  3. Type 2 diabetes is one of the most significant global health concerns of modern times. The size of the diabetes therapeutics market has stimulated a vast and growing pipeline of potential new therapies aimed at the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients. This research service evaluates ...

    $4,950.00
  4. Big pharma companies increasingly consider outsourcing manufacturing to CMOs as a strategic move because of the uncomplicated, timely, and cost-effective services CMOs provide as well as the fact that companes can then focus on their core competencies. This study provides market overview, market engineering measurements, revenue forecasts, competit...

    $4,950.00
  5. 29 Sep 2015  |  Global

    Transforming cancer treatment with Immunotherapy (TechVision)

    Fight cancer with Immunotherapy

    This research service focuses on the current status of candidates for opioid therapeutics with a focus on current Phase 3 candidates, detailed timelines, rational for pivotal program design, Phase 2 data review and key opinion leader (KOL) commentary. A pipeline assessment is provided for all active candidates in development. The information contai...

    $4,950.00
  6. 28 Sep 2015  |  Asia Pacific

    End-User Perspectives on the SEA RIS/ PACS Market

    Next-generation Imaging IT Needs Will Focus on Interoperability

    Picture archiving communication systems (PACS) were a real game changer 3 decades ago when, in combination with radiology information systems (RIS), they enabled rapid digitalization of medical imaging data. Today, Southeast Asia again stands at the brink of transformation as RIS PACS enter their second or third generation of deployment. In an effo...

    $4,950.00
  7. This issue of Vital Signs discusses the FDA's clearnace of the first 3-D printed prescription drug, Illumina's formation of consumer genomics company Helix, Response Genetics' acquisition of Cancer Genetics, and Roche's acquisition of GeneWEAVE.

    $450.00
  8. 21 Sep 2015  |  North America

    Vital Signs - Review of AHRA 2015: Key Conference Takeaways and Gadolinium Based MR Contrast Agents Safety Issues

    Overview of Top Themes from the 2015 Annual Meeting of the Association for Medical Imaging Management (AHRA)

    A record-high attendance of 1,000 radiology directors and managers convened to the 2015 Annual Meeting of the Association for Medical Imaging Management (AHRA 2015) held this year in Las Vegas. Radiology is going through interesting times indeed. Under the coordinated care paradigm that is gradually emerging in the U.S., and with all the changes th...

    $450.00
  9. 20 Sep 2015  |  North America

    Strategic Overview of Patenting Activity in Pharma Sector of BRIC Countries

    Patenting Trends, IP Policy Developments, and Strategic Insights

    Since the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research service evaluates the US market for the pharmaceutical management o...

    $4,950.00
  10. 15 Sep 2015  |  North America

    Development of Value-based Imaging

    Driving Vendor-Customer Relationships in a Value-focused Medical Imaging Environment in the United States

    A trickle-down effect from healthcare reform, together with a transformation operated from within, is pushing the medical imaging industry into a value-focused environment. Although it does seem that the volume-to-value transition in medical imaging will be more of a gradual process than an overnight change, it is already well underway. Its impact ...

    $2,450.00